Lahko na kratko poveš kaj je point? Koliko sem na hitro opazil, da je proti obsevanju? Tukaj lahko potrdim, da "pozdravi" raka, te pa počasi ubija na dolgi rok
Samo, ko si v situaciji, si težko pameten in si verjetno ne želiš malo experimentirat. Ponavadi niti nimaš časa.
Kaj ja pa je njegova metoda zdravljenja?
en.m.wikipedia.org
Antineoplaston therapy
Antineoplaston is a name coined by Burzynski for a group of
peptides, peptide derivatives, and mixtures that he uses as an
alternative cancer treatment.
[9] The word is derived from
neoplasm.
[10]
Antineoplaston therapy has been offered in the U.S. since 1984 but is not approved for general use. The compounds are not licensed as drugs but are instead sold and administered as part of clinical trials at the Burzynski Clinic and the Burzynski Research Institute.
[11][12]
Burzynski stated that he began investigating the use of antineoplastons after detecting what he considered significant differences in the presence of peptides between the blood of cancer patients and a control group.
[13] He first identified antineoplastons from human blood. Since similar peptides had been isolated from urine, early batches of Burzynski's treatment were isolated from urine.
[13] Burzynski has since produced the compounds synthetically.
[14]
The first active peptide fraction identified was called antineoplaston A-10 (3-phenylacetylamino-2,6-piperidinedione). From A-10, antineoplaston AS2-1 was derived – a 4:1 mixture of
phenylacetic acid and
phenylacetylglutamine.
[15] The Burzynski Clinic website states that the active ingredient of antineoplaston A10-I is phenylacetylglutamine.
[12]
Since 2011, the clinic has marketed itself as offering "personalized gene-targeted cancer therapy", which has stirred further controversy. David Gorski argues that the concept of "personalised cancer therapy" is "more of a marketing term than a scientifically meaningful description".
[16] According to Gorski, it appears unlikely that the Burzynski clinic would indeed be able to actually personalise gene-targeting therapies, i.e., "identify who would benefit from specific targeted therapies simply from blood tests," as Burzynski claims, since there are no proven methods to achieve this.
[16] Consequently, many reject Burzynski's claim of offering
personalised medicine, because in reality his patients are administered untested combinations of various approved and unapproved medications, without a sound rationale for a given combination and without "any concern for potential adverse reactions".
[17][18]